Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 5 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 21 hours agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 2 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 3 days agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 4 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
Amgen Inc. (NASDAQ:AMGN) Sees Significant Drop in Short Interest
ETF DAILY NEWS· 6 days agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) was the recipient of a large decrease in short interest in May. As of May 31st, there was short interest totalling 9,050,000 shares, a decrease of ...
Gerber LLC Makes New $342,000 Investment in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 6 days agoGerber LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission ...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 2 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
AbbVie (NYSE:ABBV) Given New $190.00 Price Target at Piper Sandler
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Get Free Report) had its price objective boosted by research analysts at Piper Sandler from $185.00 to $190.00 in a research note issued on Tuesday, Benzinga reports. Piper ...
A New Psychotherapeutic 'Gold Standard' for Chronic Pain?
Medscape· 4 days agoA single course of treatment with emotional awareness and expression therapy (EAET) was associated...